Insider Transactions in Q1 2023 at Meridian Bioscience Inc (VIVO)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2023
|
John Mc Cune Rice Jr. Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,449
-100.0%
|
-
|
|
Jan 31
2023
|
Catherine Sazdanoff Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,424
-100.0%
|
-
|
|
Jan 31
2023
|
Felicia Williams Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,274
-100.0%
|
-
|
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
-
|
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,224
-100.0%
|
-
|
|
Jan 31
2023
|
Anthony P Bihl Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,408
-100.0%
|
-
|
|
Jan 31
2023
|
Dwight E Ellingwood Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,290
-100.0%
|
-
|
|
Jan 31
2023
|
John Mc Ilwraith Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,724
-100.0%
|
-
|
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,338
-100.0%
|
-
|
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+15.49%
|
-
|
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Sale (or disposition) back to the issuer
|
Direct |
86,045
-100.0%
|
-
|
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+8.45%
|
-
|
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,473
-100.0%
|
-
|
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+28.98%
|
-
|
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
267,651
-100.0%
|
-
|
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,060
+14.95%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
25,600
-100.0%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
32,708
-100.0%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,648
+7.49%
|
-
|
|
Jan 06
2023
|
James M. Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+23.15%
|
$170,000
$20.38 P/Share
|